Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Colorectal Neoplasms 445Carcinoma, Non-Small-Cell Lung 224Breast Neoplasms 189Ovarian Neoplasms 167Glioblastoma 156Neoplasms 126Carcinoma, Hepatocellular 124Rectal Neoplasms 112Colonic Neoplasms 107Neoplasm Metastasis 104Brain Neoplasms 96Lung Neoplasms 91Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 71Glioma 69Pancreatic Neoplasms 54Gliosarcoma 43Melanoma 42Liver Neoplasms 42Uterine Cervical Neoplasms 40Stomach Neoplasms 37Adenocarcinoma of Lung 36Recurrence 33Astrocytoma 30Endometrial Neoplasms 27Carcinoma, Ovarian Epithelial 27Triple Negative Breast Neoplasms 26Prostatic Neoplasms 22Kidney Neoplasms 22Esophageal Neoplasms 21

Interventions

Bevacizumab 21-dodecylpyridoxal 2tremelimumab 1durvalumab 1Paclitaxel 1Injections 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Platinum-resistant Recurrent Ovarian Cancer × Bevacizumab × Clear all
NCT06509971 2024-07-19

A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

West China Second University Hospital

Phase 2 Not yet recruiting
39 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡